The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Predictors of Competing Mortality in Advanced Head and Neck Cancer
Open accessAbstract
Purpose: Death from noncancer causes (competing mortality) is an important event in head and neck cancer, but studies identifying predictors of this event are lacking. We sought to identify predictors of competing mortality and develop a risk stratification model for competing events. Patients and Methods: Cohort study of 479 patients with stage III to IV carcinoma of the head and neck diagnosed between August 1993 and November 2004. Patients were treated on consecutive prospective clinical trials involving organ-preserving chemoradiotherapy and surgery. We used multivariable competing risks regression models to analyze factors associated with the cumulative incidence of competing mortality, locoregional and distant failure, and second malignancies as first events. Results: Median follow-up was 52 months median for survivors. The 5-year cumulative incidence of competing mortality was 19.6% (95% CI, 15.8 to 23.4). On multivariable analysis, competing mortality was associated with female sex (hazard ratio [HR], 1.72; 95% CI, 1.13 to 2.63), increasing age (HR, 1.30; 95% CI, 1.04 to 1.62), increasing Charlson Comorbidity Index (HR, 1.24; 95% CI, 1.05 to 1.47), decreasing body mass index (HR, 0.33; 95% CI, 0.13 to 0.84), and decreasing distance traveled to the treating center (HR, 0.65; 95% CI, 0.44 to 0.98). Patients with zero, one, two, and ≥ three risk factors had 5-year competing mortality of 8.9% (95% CI, 3.0% to 14.8%), 12.4% (95% CI, 7.0% to 17.8%), 22.1% (95% CI, 14.5% to 29.7%), and 39.3% (95% CI, 28.6% to 50.1%), respectively. Conclusion: Competing mortality in advanced head and neck cancer is associated with several demographic and health status characteristics. Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Slaughter, D. P., Southwick, H. W., & Smejkal, W. (1953) · Cancer · doi:10.1002/1097-0142(195309)6:5<963::aid-cncr2820060515>3.0.co;2-q · Cited by 3,545
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,269
Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J.-L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032641 · Cited by 3,192
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M., Pajak, T. F., Weber, R., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,174
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070956 · Cited by 1,705
The Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003) · JAMA · doi:10.1001/jama.289.19.2554 · Cited by 783
Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M.-H., & Carroll, P. R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm168 · Cited by 520
Gaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483
Competing Risks: A Practical Perspective
Pintilie, M. (2006) · Cited by 443
Comorbidity and Survival Disparities Among Black and White Patients With Breast Cancer
Tammemagi, C. M. (2005) · JAMA · doi:10.1001/jama.294.14.1765 · Cited by 432
Brockstein, B., Haraf, D. J., Rademaker, A. W., Kies, M. S., Stenson, K. M., Rosen, F., Mittal, B. B., Pelzer, H., Fung, B. B., Witt, M.-E., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh308 · Cited by 370
Self-citationCompeting Risks: A Practical Perspective
Pintilie, M. (2006) · Wiley eBooks · doi:10.1002/9780470870709 · Cited by 364
Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma
Hanrahan, E. O., Gonzalez-Angulo, A. M., Giordano, S. H., Rouzier, R., Broglio, K. R., Hortobagyi, G. N., & Valero, V. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0499 · Cited by 315
Vokes, E. E., Stenson, K., Rosen, F. R., Kies, M. S., Rademaker, A. W., Witt, M. E., Brockstein, B. E., List, M. A., Fung, B. B., Portugal, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.006 · Cited by 234
Self-citationIs Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Lamont, E. B., Hayreh, D., Pickett, K. E., Dignam, J. J., List, M. A., Stenson, K. M., Haraf, D. J., Brockstein, B., Sellergren, S. A., & Vokes, E. E. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg035 · Cited by 150
Self-citationApplications of crude incidence curves
Korn, E. L., & Dorey, F. J. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110611 · Cited by 132
Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Munoz, A., & Samet, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh065 · Cited by 113
Haraf, D. J., Rosen, F. R., Stenson, K. M., Argiris, A. E., Mittal, B. B., Witt, M. E., Brockstein, B., List, M. A., Portugal, L. G., Pelzer, H. J., et al. (2003) · PubMed · Cited by 74
Self-citationCompeting risks determining event-free survival in early breast cancer
Arriagada, R., Rutqvist, L., Kramar, A., & Johansson, H. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.391 · Cited by 58
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
The Role of Autophagy in Cancer: Therapeutic Implications
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0047 · Cited by 1,215
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Metadata
- Authors
- Mell, L. K., Dignam, J. J., Salama, J. K., Cohen, E. E. W., Polite, B. N., Dandekar, V., Bhate, A. D., Witt, M. E., Haraf, D. J., Mittal, B. B., Vokes, E. E., & Weichselbaum, R. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-01
- Volume
- 28
- Issue
- 1
- Pages
- 15-20
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2134123784
- Cited by
- 433
- References
- 28
- FWCI
- 58.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.